NPPB and cancer: Our data support previous evidence that early assessment of subclinical cardiotoxicity (using measurement of Tn I, NT-proBNP, GLS, and MW indices) in patients undergoing cardiotoxic cancer therapy may lead to early detection of LV dysfunction and timely initiation of appropriate management to prevent serious complications and improve survival in cancer patients.